ArticleAnnals of translational medicine2022
Acteoside attenuates hydrogen peroxide-induced injury of retinal ganglion cells via the CASC2/miR-155/mTOR axis.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- CTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucoma.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Ferroptosis regulator NOX1 acts a diagnostic biomarker and mediates disease progression with the transcriptional regulation of STAT3 in glaucoma.Indian journal of ophthalmology · 2026Article
- Blindness following hydrogen peroxide ingestion and recovery with hyperbaric oxygen therapy.Toxicology reports · 2025Article
- The diagnostic and predictive potential of lncRNA CASC2 targeting miR-155 in systemic lupus erythematosus patients with nephritis complication.Scientific reports · 2024Article
- Melatonin antagonizes oxidative stress-induced apoptosis in retinal ganglion cells through activating the thioredoxin-1 pathway.Molecular and cellular biochemistry · 2024Article
- Exploring Epigenetic Modifications as Potential Biomarkers and Therapeutic Targets in Glaucoma.International journal of molecular sciences · 2024Review
- Neuroprotective effects of acteoside in a glaucoma mouse model by targeting Serta domain-containing protein 4.International journal of ophthalmology · 2024Article
- Article
- A Case Study from the Past: "The RGC-5 vs. the 661W Cell Line: Similarities, Differences and Contradictions-Are They Really the Same?"International journal of molecular sciences · 2023Article
- Integrated analysis of long non-coding RNAs and mRNAs associated with glaucomaFrontiers in endocrinology · 2023Article
- The pharmacokinetic property and pharmacological activity of acteoside: A review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLoss of retinal ganglion cells (RGCs), which eventually leads to optic nerve atrophy and vision loss, is the main cause of glaucoma and traumatic optic neuropathy. Acteoside is the effective component of Yunnan Kudingcha, which has been reported to exert neuroprotective effects and protects RGCs from injury. However, the underlying mechanisms of acteoside in RGC injury remain largely elusive.
methodsHuman RGCs was treated with hydrogen peroxide (H
resultsWe identified the expression of miR-155 was upregulated in H
conclusionsActeoside protects RGC-5 cells against H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.